Clinical Trial Update: Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency [Phase 2]

View source ↗

Summary

Phase 2 extension study evaluating long-term safety, tolerability, and efficacy of Sebelipase alfa (SBC-102) in adults with lysosomal acid lipase deficiency. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholesterol Ester Storage Disease
• Lysosomal Acid Lipase Deficiency

Drugs mentioned

• Sebelipase alfa (sebelipase alfa)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Cholesterol Ester Storage Disease (CESD), Lysosomal Acid Lipase Deficiency | Phase 2 | Status: COMPLETED | Results posted: 2016-05-09